1 / 168

Pulmonary Diseases

Pulmonary Diseases. by: Eddie K. Lam M.D. RESPIRTORY DISEASES. COUGH COPD ASTHMA CHRONIC BRONCHITIS EMPHYSEMA TUBERCULOSIS PULMONARY NODULES ALPHA 1 ANTITRYPSIN DEFICIENCY PLEURISY PLEURAL EFFUSION PNEUMOTHORAX VENOUS THROMBOLISM. COUGH.

maura
Download Presentation

Pulmonary Diseases

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Pulmonary Diseases by: Eddie K. Lam M.D.

  2. RESPIRTORY DISEASES • COUGH • COPD • ASTHMA • CHRONIC BRONCHITIS • EMPHYSEMA • TUBERCULOSIS • PULMONARY NODULES • ALPHA 1 ANTITRYPSIN DEFICIENCY • PLEURISY • PLEURAL EFFUSION • PNEUMOTHORAX • VENOUS THROMBOLISM

  3. COUGH • Acute cough ( last < 3 weeks) • Subacute (3 to 8 weeks) • Chronic ( longer than 8 weeks)

  4. Acute cough • Most commonly associated with common cold • Differentiate between serious condition such as pulmonary embolism, CHF, pneumonia, asthma, COPD, • Antihistamine or decongestant should be prescribed

  5. Subacute cough • Is the cough follow a respiratory infection • Cough began with URI and lingered indicate postinfectious cough • Postnasal drip, upper airway irritation, mucus accumulation, airway spasm

  6. Chronic cough • Smoking • Medications • Asthma • GERD • Upper airway cough syndrome • Nonasthmatic eosinophilic bronchitis • Cancer • Atypical infection

  7. History and physical Lam’s criteria for cough • Smoking • Throat irritation • Ups or downs • Productive • Itching • Duration • Nasal drip, congestion • Eating • Position • Hemoptysis • E • Weight loss

  8. Physical exam • HEENT • Chest, heart • Lymph nodes • Skins/fingers

  9. Chest x ray • Reasonable as baseline if cough persists more than 3 weeks • Suspect pneumonia • Weight loss • Hemoptysis • Nightsweats

  10. Treatment of cough • URI- 1st generation antihistamine + decongestant • Upper airway- inhaled nasal steroids • Bacterial- appropriate antibiotics + suppressants • Codeine Vs DM • Brochospasm- Anticholinergic agents • Drug induced- Discontinue ACE inhibitors

  11. treatment cont. • Inhaled corticosteroids • Oral corticosteroids

  12. If all treatment failed • No way • Suspect noncompliance • Suspect other causes: GERD, swallowing disorder • Consider bronchoprovocation test • ? CT • Refer to specialist

  13. COPD • CHRONIC OBSTRUCTIVE PULMONARY DISEASE

  14. Chronic obstructive pulmonary disease Definition: an inflammatory respiratory disease, mostly by tobacco smoke Exposure to cigarette smoking, airway inflammation, airflow obstruction that is not fully reversible

  15. COPD • Chronic bronchitis and emphysema are no longer included in the definition of COPD, though still used clinically • Asthma is the most often confused with COPD

  16. Risk factors • Cigarette smoking • Persons who smoke, 12-13 times likely to die from COPD • 2nd hand smoke • Advancing age • Environmental or occupational pollutants • Alpha 1 antitrypsin deficiency • Family history of COPD

  17. Occupational exposures • Mineral dust: coal mining, tunnel work, concrete, silica exposure • Organic dust: Cotton, flax, • Noxious gas: Sulfur dioxide, isocyanates, heavy metal, welding fumes

  18. pathophysiology • Chronic airway irritation • Mucus production > decreased mucociliary function • Pulmonary scarring/airway scarring • Leads to hallmark of COPD Sx.> coughing and sputum production > • Progressive airway obstruction and dyspnea

  19. COPD is more common and fatal in women than men • Lung size • More hyperresponsive to irritants

  20. Clinical history • Hallmark Symptoms • Cough, increased sputum production, dyspnea (good predictor of mortality) • Less common : edema, chest tightness, weight loss, nocturnal awakenings

  21. Differential diagnosis ??????????

  22. Differential diagnosis • Asthma • CHF • Bronchiectasis • Lung cancer • Interstitial lung disease/fibrosis • TB

  23. Clinical history • Patient and family history • History of tobacco use • Pack years = number of packs smoked per day multiplied by number of years smoked • Occupational history • Job activities

  24. Family history of Alpha 1 antitrypsin deficiency, genetic anomaly of chromosome 14 leads to premature hepatic and pulmonary disease • Increase tissue damage from neutrophil elastase> alveolar damage> loss of elastic recoil> airway obstruction

  25. Alpha 1 antitrypsin deficiciency • 59,000 Americans have Sx. COPD caused by alpha 1 antitrypsin deficiency • Screening in symptomatic adults with persistent obstruction on pulmonary function test

  26. Physical exam • Not sensitive initially • Lung hyperinflation • Widened A-P chest diameter • Hyperresonance on percussion • Cor pulmonale- peripheral edema, JVD, hepatomegaly • Cyanosis, cachexia • Clubbing (rare), looking for cancer,fibrosis, brochectasis

  27. Diagnostic testing • SPIROMETRY • Should perform in all smokers 45years or older • Key features: FEV1 • FVC ( forced vital capacity)

  28. FEV1 – the volume of air patient can expire in one second following full inspiration • FVC -- total maximum volume of air patient can exhale after a full inspiration

  29. Diagnosis of COPD • Postbronchodilator FEV1/FVC ratio of less than 0.7 associated with FEV1 less than 80% of predicted value is diagnostic of airflow limitation and confirms COPD • Peak expiratory flow rates are not helpful in diagnosis of COPD

  30. Other diagnostic test • Spirometry is the key test • CXR • CT chest • EKG • CBC • Pulse oximetry

  31. pharmacotherapy • Bronchodilator • Bronchodilator • Bronchodilator • Bronchodilator • Bronchodilator • bronchodilator

  32. Short acting beta 2 agonists • Beta 2 agonists: stimulate beta 2 receptors, increase cyclic AMP, increase smooth muscle relaxation, lung emptying and air trapping • Short acting: Proventil, Ventolin, Proair, Xopenex • Side effects: Tachycardia, cardiac disturbance, tremors

  33. Long acting beta 2 agonists • Maintenance therapy • Longer lasting improvement • Salmeterol (Serevent Diskus) • Formoterl (Foradil)

  34. Short acting Anticholinergic agents • Smooth muscle relaxation of airways • Antagonism of acetycholine at M3 receptors on airway • Slower onset of action than beta 2 but longer duration • Side effects: Caution w/ glaucoma, BPH • Ipratropium (Atrovent)

  35. Long acting Anticholinergic agents • Sustained action over 24 hours • Tiotropium (Spiriva) • 24% lower of number exacerbation than Ipratropium

  36. Corticosteroids • Act at multiple points in inflammatory process • Increase FEV1 • NOT APPROVED FOR SINGLE USE AGENT IN COPD • Recommend as addition to maintenance therapy • Side effects: bruising, candidiasis, voice alteration

  37. Combination therapies • Beta 2 + anticholinergic agent (Combivent) • Corticosteroid + long acting Beta 2 (Advair) (Symbicort)

  38. Acute exacerbation of COPD • Sustained worsening of patient’s condition from stable state and beyond normal day to day variations, that is acute in onset and necessitates a change in regular medication in a patient with underlying COPD

  39. Infectious agents • 80% gram positive and gram negative bacteria • Nosocomial • 30% viruses • 5-10% atypical bacteria

  40. Treatment other than bronchodilators • Antibiotics • Smoking cessation • Pulmonary Rehabilitation • Oxygen therapy: PaO2 < 55mmHg or O2 sat < 88% • Long term use increase survival

  41. AGE >40 10 pk yrs Sputum often Allergies infreq. Progressive worse Clinical Sx. Persistent Airflow partial reversible <40 Usually none/min Infrequent Often Nonprogressive Variable Complete reversible COPD ASTHMA

  42. ASTHMA

  43. ASTHMA • Underlying cause of 40% young adults being evaluated for dyspnea • Pulmonary testing plays a major role

  44. Common risk factors for asthma – host factors • Genetic • Female sex • Low birth weight • Obesity • Atopy/allergies • eczema

  45. Environmental factors • Prenatal and childhood exposure to tobacco smoke • Lack of breast feeding • Severe respiratory infections in 1st year of life • Indoor allergens and outdoor pollutants • Occupational exposures

  46. Clinical presentation • Waxing and waning symptoms of dyspnea, cough, wheezing and chest tightness • Exacerbation of symptoms usually gradual in onset and cessation

  47. Triggers • Exposure to common allergens • Cold weather • Viral infections • Physical exercise

  48. Physical exam • Frequently normal • Stigmata of allergic rhinitis • Eczema • Airflow obstruction/wheezing (poor predictor value)

  49. Laboratory tests • CXR • Pulse oximetry • CBC

  50. Spiromery • NAEPP (National Asthma Education and Preventive Program) recommends using spirometry for initial diagnosis and long term follow up of Asthma • Perform at initial assessment • After treatment initiated • Stabilized and during period of prolonged loss of asthma control and at least every 1 to 2 yrs

More Related